Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases

Brain metastases from non-medullary thyroid carcinoma (NMTC) are rare, with a reported frequency of ~1%, and patient survival time is 2 years, supporting an aggressive treatment approach.

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-01, Vol.15 (1), p.672-676
Main Authors: Slutzky-Shraga, Ilana, Gorshtein, Alex, Popovitzer, Aharon, Robenshtok, Eyal, Tsvetov, Gloria, Akirov, Amit, Hirsch, Dania, Benbassat, Carlos
Format: Article
Language:English
Subjects:
Bones
Brain cancer
Brain tumors
Cancer metastasis
Cancer therapies
Care and treatment
Complications and side effects
Delirium
Development and progression
Iodine
Liver
Medical diagnosis
Medical imaging
Medical prognosis
Metastasis
NMR
Nuclear magnetic resonance
Oncology
Patients
Radiation therapy
Surgery
Thyroid cancer
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Brain metastases from non-medullary thyroid carcinoma (NMTC) are rare, with a reported frequency of ~1%, and patient survival time is 2 years, supporting an aggressive treatment approach.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2017.7325